Research any topic before you write.
Find related topics. | Discover entities. | See connections. | Build a topical map.
Sunitinib, sold under the brand name Sutent, is an anti-cancer medication. It is a small-molecule, multi-targeted receptor tyrosine kinase (RTK) inhibitor that was approved by the FDA for the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST) in January 2006. Sunitinib was the first cancer drug…
History, Community, Culture & Applications
Explore the main themes, entities and connections around Sunitinib. Start with the topic map, then use the sections below for research and deeper semantic analysis.
Start with a few of the strongest sections from the source topic. These are research directions, not a list of keywords you must use.
High-confidence facts extracted from structured source data. Use them as anchors for further research.
Browse the full topic structure. Each item opens a new analysis centered on that subject.
Deeper signals for content research, entity SEO and topical coverage. The plain-language headings explain what each technical view is useful for.
See the strongest relationship patterns around the current topic before diving into the raw triples.
Use these terms to understand the vocabulary surrounding the topic, not as a checklist for keyword stuffing.
patients cell metastatic treatment renal cancer tumors placebo disease adverse carcinoma study ifnα tumor sutent therapy gastrointestinal stromal progression events
| Subject | Predicate | Object | Confidence | Src |
|---|---|---|---|---|
| Sunitinib | 3D model (JSmol) | Interactive image | 1.00 | infobox |
| Sunitinib | AHFS/Drugs.com | Monograph | 1.00 | infobox |
| Sunitinib | ATC code | L01EX01 (WHO) | 1.00 | infobox |
| Sunitinib | Bioavailability | Unaffected by food | 1.00 | infobox |
| Sunitinib | CAS Number | 557795-19-4 Y | 1.00 | infobox |
| Sunitinib | CAS Number | as salt: 341031-54-7 Y | 1.00 | infobox |
| Sunitinib | ChEBI | CHEBI:38940 Y | 1.00 | infobox |
| Sunitinib | ChEMBL | ChEMBL535 Y | 1.00 | infobox |
| Sunitinib | ChEMBL | as salt: ChEMBL1567 | 1.00 | infobox |
| Sunitinib | ChemSpider | 4486264 Y | 1.00 | infobox |
| Sunitinib | ChemSpider | as salt: 4958254 | 1.00 | infobox |
| Sunitinib | CompTox Dashboard (EPA) | DTXSID1041134 | 1.00 | infobox |
| Sunitinib | DrugBank | DB01268 Y | 1.00 | infobox |
| Sunitinib | DrugBank | as salt: DBSALT000166 | 1.00 | infobox |
| Sunitinib | Elimination half-life | 40 to 60 hours (sunitinib) 80 to 110 hours (metabolite) | 1.00 | infobox |
| Sunitinib | Excretion | Fecal (61%) and kidney (16%) | 1.00 | infobox |
| Sunitinib | Formula | C22H27FN4O2 | 1.00 | infobox |
| Sunitinib | IUPHAR/BPS | 5713 | 1.00 | infobox |
| Sunitinib | KEGG | D08552 Y | 1.00 | infobox |
| Sunitinib | KEGG | as salt: D06402 | 1.00 | infobox |
| Sunitinib | Legal status | AU: S4 (Prescription only) | 1.00 | infobox |
| Sunitinib | Legal status | US: ℞-only | 1.00 | infobox |
| Sunitinib | Legal status | EU: Rx-only | 1.00 | infobox |
| Sunitinib | License data | US DailyMed: Sunitinib | 1.00 | infobox |
| Sunitinib | MedlinePlus | a607052 | 1.00 | infobox |
| Sunitinib | Metabolism | Liver (CYP3A4-mediated) | 1.00 | infobox |
| Sunitinib | Molar mass | 398.482 g·mol−1 | 1.00 | infobox |
| Sunitinib | Other names | SU11248 | 1.00 | infobox |
| Sunitinib | Pregnancy category | AU: D | 1.00 | infobox |
| Sunitinib | Protein binding | 95% | 1.00 | infobox |
These clusters group vocabulary that occurs around closely connected concepts in the source material.
Bridges can reveal useful research angles that are easy to miss in a flat list of related terms.